Hemispherx Biopharma Inc, HEB Securities Lawsuit

Company:	Hemispherx Biopharma Inc,
Ticker Symbol:	HEB
Class Period:	Mar-19-12 to Dec-17-12
Date Filed:	Dec-21-12
Lead Plaintiff Deadline:	Feb-19-13
Court:	---
Allegations:

New York, NY: A securities class action lawsuit has been filed on behalf of investors who purchased the securities of Hemispherx Biopharma Inc, HEB -from March 19, 2012 through December 17, 2012.

The Complaint asserts violations of the federal securities laws against Hemispherx and its officers and directors for issuing false and misleading information about its lead drug candidate Ampligen. Specifically, that Hemispherx misstated the safety and efficacy of Ampligen, and touted purportedly positive results from Ampligen's clinical trials.

On December 18, 2012, the FDA published a staff report concluding that the Company's studies were "ill-defined and invalid" with signals of efficacy that were inconsistent between clinical trials, and based on the limited quality of the data, "it is difficult to draw conclusions regarding potential safety signals," but the "review identified nine potential safety concerns associated with Ampligen." The Complaint alleges that as a result of this adverse information, Hemispherx stock price dropped and investors have been damaged.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Hemispherx Biopharma Inc, HEB Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Hemispherx Biopharma Inc, securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.
Published on Dec-24-12